Predicting impulse control disorder in Parkinson’s Disease: Is there a formula?

Related Articles:

• Predicting impulse control disorder in Parkinson's Disease: Is there a formula? March 17, 2023 Eur Neuropsychopharmacol. 2023 Mar 15;72:4-5. doi: 10.1016/j.euroneuro.2023.02.017. Online ahead of print.NO ABSTRACTPMID:36930990 | DOI:10.1016/j.euroneuro.2023.02.017
• Predicting impulse control disorder in Parkinson's Disease: Is there a formula? March 17, 2023 Eur Neuropsychopharmacol. 2023 Mar 15;72:4-5. doi: 10.1016/j.euroneuro.2023.02.017. Online ahead of print.NO ABSTRACTPMID:36930990 | DOI:10.1016/j.euroneuro.2023.02.017
• Predicting impulse control disorder in Parkinson's Disease: Is there a formula? March 17, 2023 Eur Neuropsychopharmacol. 2023 Mar 15;72:4-5. doi: 10.1016/j.euroneuro.2023.02.017. Online ahead of print.NO ABSTRACTPMID:36930990 | DOI:10.1016/j.euroneuro.2023.02.017
• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase February 21, 2022 Eur Neuropsychopharmacol. 2022 Feb 18;58:30-38. doi: 10.1016/j.euroneuro.2022.01.113. Online ahead of print.ABSTRACTBACKGROUND: Dopamine receptor agonist drugs, which are used, for example, to treat Parkinson's disease (PD), increase the risk for impulse control disorders (ICDs), potentially resulting in devastating psychosocial consequences. It is unknown whether other drugs with dopaminergic properties also increase the risk for ICDs. This study assesses the disproportionality of…
• Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase February 21, 2022 Eur Neuropsychopharmacol. 2022 Feb 18;58:30-38. doi: 10.1016/j.euroneuro.2022.01.113. Online ahead of print.ABSTRACTBACKGROUND: Dopamine receptor agonist drugs, which are used, for example, to treat Parkinson's disease (PD), increase the risk for impulse control disorders (ICDs), potentially resulting in devastating psychosocial consequences. It is unknown whether other drugs with dopaminergic properties also increase the risk for ICDs. This study assesses the disproportionality of…
• Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase February 21, 2022 Eur Neuropsychopharmacol. 2022 Feb 18;58:30-38. doi: 10.1016/j.euroneuro.2022.01.113. Online ahead of print.ABSTRACTBACKGROUND: Dopamine receptor agonist drugs, which are used, for example, to treat Parkinson's disease (PD), increase the risk for impulse control disorders (ICDs), potentially resulting in devastating psychosocial consequences. It is unknown whether other drugs with dopaminergic properties also increase the risk for ICDs. This study assesses the disproportionality of…
• Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase February 21, 2022 Eur Neuropsychopharmacol. 2022 Feb 18;58:30-38. doi: 10.1016/j.euroneuro.2022.01.113. Online ahead of print.ABSTRACTBACKGROUND: Dopamine receptor agonist drugs, which are used, for example, to treat Parkinson's disease (PD), increase the risk for impulse control disorders (ICDs), potentially resulting in devastating psychosocial consequences. It is unknown whether other drugs with dopaminergic properties also increase the risk for ICDs. This study assesses the disproportionality of…
• Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson's disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial June 13, 2022 Chin Med. 2022 Jun 13;17(1):68. doi: 10.1186/s13020-022-00625-4.ABSTRACTBACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disease common in aged populations. Classified by Hoehn & Yahr stages, patients are often divided into mild/early stage, moderate/middle stage, and advanced/late stage. With disease progression, PD shows high heterogeneity in each stage. Based on traditional Chinese medicine (TCM) syndrome differentiation theory and our previous works,…
• Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson's disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial June 13, 2022 Chin Med. 2022 Jun 13;17(1):68. doi: 10.1186/s13020-022-00625-4.ABSTRACTBACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disease common in aged populations. Classified by Hoehn & Yahr stages, patients are often divided into mild/early stage, moderate/middle stage, and advanced/late stage. With disease progression, PD shows high heterogeneity in each stage. Based on traditional Chinese medicine (TCM) syndrome differentiation theory and our previous works,…
• Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson's disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial June 13, 2022 Chin Med. 2022 Jun 13;17(1):68. doi: 10.1186/s13020-022-00625-4.ABSTRACTBACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disease common in aged populations. Classified by Hoehn & Yahr stages, patients are often divided into mild/early stage, moderate/middle stage, and advanced/late stage. With disease progression, PD shows high heterogeneity in each stage. Based on traditional Chinese medicine (TCM) syndrome differentiation theory and our previous works,…
• Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson's disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial June 13, 2022 Chin Med. 2022 Jun 13;17(1):68. doi: 10.1186/s13020-022-00625-4.ABSTRACTBACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disease common in aged populations. Classified by Hoehn & Yahr stages, patients are often divided into mild/early stage, moderate/middle stage, and advanced/late stage. With disease progression, PD shows high heterogeneity in each stage. Based on traditional Chinese medicine (TCM) syndrome differentiation theory and our previous works,…
• Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson's disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial June 13, 2022 Chin Med. 2022 Jun 13;17(1):68. doi: 10.1186/s13020-022-00625-4.ABSTRACTBACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disease common in aged populations. Classified by Hoehn & Yahr stages, patients are often divided into mild/early stage, moderate/middle stage, and advanced/late stage. With disease progression, PD shows high heterogeneity in each stage. Based on traditional Chinese medicine (TCM) syndrome differentiation theory and our previous works,…
• Classification of Parkinson's disease and its stages using machine learning August 18, 2022 Sci Rep. 2022 Aug 18;12(1):14036. doi: 10.1038/s41598-022-18015-z.ABSTRACTAs digital health technology becomes more pervasive, machine learning (ML) provides a robust way to analyze and interpret the myriad of collected features. The purpose of this preliminary work was to use ML classification to assess the benefits and relevance of neurocognitive features both tablet-based assessments and self-reported metrics, as they relate to Parkinson's…
• Classification of Parkinson's disease and its stages using machine learning August 18, 2022 Sci Rep. 2022 Aug 18;12(1):14036. doi: 10.1038/s41598-022-18015-z.ABSTRACTAs digital health technology becomes more pervasive, machine learning (ML) provides a robust way to analyze and interpret the myriad of collected features. The purpose of this preliminary work was to use ML classification to assess the benefits and relevance of neurocognitive features both tablet-based assessments and self-reported metrics, as they relate to Parkinson's…
• Classification of Parkinson's disease and its stages using machine learning August 18, 2022 Sci Rep. 2022 Aug 18;12(1):14036. doi: 10.1038/s41598-022-18015-z.ABSTRACTAs digital health technology becomes more pervasive, machine learning (ML) provides a robust way to analyze and interpret the myriad of collected features. The purpose of this preliminary work was to use ML classification to assess the benefits and relevance of neurocognitive features both tablet-based assessments and self-reported metrics, as they relate to Parkinson's…
• Classification of Parkinson's disease and its stages using machine learning August 18, 2022 Sci Rep. 2022 Aug 18;12(1):14036. doi: 10.1038/s41598-022-18015-z.ABSTRACTAs digital health technology becomes more pervasive, machine learning (ML) provides a robust way to analyze and interpret the myriad of collected features. The purpose of this preliminary work was to use ML classification to assess the benefits and relevance of neurocognitive features both tablet-based assessments and self-reported metrics, as they relate to Parkinson's…
• Classification of Parkinson's disease and its stages using machine learning August 18, 2022 Sci Rep. 2022 Aug 18;12(1):14036. doi: 10.1038/s41598-022-18015-z.ABSTRACTAs digital health technology becomes more pervasive, machine learning (ML) provides a robust way to analyze and interpret the myriad of collected features. The purpose of this preliminary work was to use ML classification to assess the benefits and relevance of neurocognitive features both tablet-based assessments and self-reported metrics, as they relate to Parkinson's…
• Classification of Parkinson's disease and its stages using machine learning August 18, 2022 Sci Rep. 2022 Aug 18;12(1):14036. doi: 10.1038/s41598-022-18015-z.ABSTRACTAs digital health technology becomes more pervasive, machine learning (ML) provides a robust way to analyze and interpret the myriad of collected features. The purpose of this preliminary work was to use ML classification to assess the benefits and relevance of neurocognitive features both tablet-based assessments and self-reported metrics, as they relate to Parkinson's…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• The radiologist at a Parkinson’s conference October 24, 2022 # # # # In 2015, a woman with dementia was sitting in hospice care, wheelchair-bound and largely non-communicative. As part of a research project, she was given repeated computed tomography (CT) scans of her brain. The effect of this seemingly harmless treatment was rather astonishing, and it has led to more research exploring the effect of low dose ionizing…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…